Precigen (PGEN) Cash from Financing Activities (2012 - 2026)
Precigen (PGEN) reported Cash from Financing Activities of $109000.0 for Q1 2026, up 116.05% year-over-year from $50450.6 in Q1 2025, and up 121.21% quarter-over-quarter from -$514000.0 in Q4 2025.
Precigen (PGEN) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Cash from Financing Activities data on file, last reported at $109000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $109000.0, up 116.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.8 million (down 17.35% YoY), and the FY2025 annual result was $90.0 million, down 18.57% from the prior year.
- Cash from Financing Activities climbed to $109000.0 in Q1 2026 per PGEN's latest filing, from -$514000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $93.0 million in Q3 2025 and troughed at -$115.7 million in Q3 2022.
- A 5-year average of $5.4 million and a median of -$138000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 49558.97% in 2022, then jumped 27200.61% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$39.3 million in 2022, then surged by 62.87% to -$14.6 million in 2023, then surged by 637.57% to $78.4 million in 2024, then plunged by 100.66% to -$514000.0 in 2025, then jumped by 121.21% to $109000.0 in 2026.
- Business Quant data shows PGEN's Cash from Financing Activities at $109000.0 in Q1 2026, -$514000.0 in Q4 2025, and $93.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | 109,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,000.00 |
| Mar 31, 2026 | 109,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Dec 31, 2025 | -514,000.00 |
| Sep 30, 2025 | 93.01 Mn |
| Sep 30, 2025 | 93.01 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -679,000.00 |
| Mar 31, 2025 | -679,000.00 |
| Dec 31, 2024 | 78.40 Mn |
| Dec 31, 2024 | 78.40 Mn |
| Sep 30, 2024 | 32.13 Mn |
| Sep 30, 2024 | 32.13 Mn |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2023 | -14.59 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | 44.17 Mn |
| Mar 31, 2023 | 44.17 Mn |